50474-970 : Briviact 50 mg/5ml Intravenous Injection, Suspension
| NDC: | 50474-970 |
| Labeler: | Ucb, Inc. |
| Product Type: | Human Prescription Drug |
| Drug Name: |  Briviact |
| Dosage Form: | Intravenous Injection, Suspension |
| Application #: | NDA205837 |
| Rev. Date: | |
| CSA Schedule: | CV (US) [1] |
[1] Schedule V Controlled Substance: Low potential for abuse relative to substances listed in Schedule IV and consist primarily of preparations containing limited quantities of certain narcotics. (i.e. Cough preparations containing not more than 200 milligrams of Codeine per 100 milliliters or per 100 grams [such as Robitussin AC, Phenergan with Codeine], and Ezogabine). More Details: US Dept of Justice Controlled Substance Schedules.
NDC Package Codes:
- 50474-970-75: 10 VIAL, GLASS IN 1 CARTON (50474‑970‑75) > 5 ML IN 1 VIAL, GLASS (50474‑970‑63)
Active Ingredients:
- Brivaracetam
Dosage Strength:
- 50 mg/5mL
Pharmaceutical Classes:
- Epoxide Hydrolase Inhibitors [MoA]
Related Products:
Based on records with the same trade name.- 50474-370 Briviact 10 mg Oral Tablet, Film Coated by Ucb, Inc.
- 50474-470 Briviact 25 mg Oral Tablet, Film Coated by Ucb, Inc.
- 50474-570 Briviact 50 mg Oral Tablet, Film Coated by Ucb, Inc.
- 50474-670 Briviact 75 mg Oral Tablet, Film Coated by Ucb, Inc.
- 50474-770 Briviact 100 mg Oral Tablet, Film Coated by Ucb, Inc.
- 50474-870 Briviact 10 mg/ml Oral Solution by Ucb, Inc.
NDC QR Code
Scan the QR code below to easily reference this data in the future:
< Prev: 50474-932Next: 50474-980 >
Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.